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Neonatology 2010;98:217-224 218 pairments and disabilities than very preterm infants who survive without BPD [1] .
Corticosteroids are powerful drugs which may improve lung function in infants with BPD by a number of different mechanisms. It has been suggested that they might have a role to play in the prevention of BPD by suppressing the inflammatory response in the lung of babies at risk [2] . Babies who develop BPD have low cortisol levels following ACTH stimulation during the first week of life [3] . To be effective in preventing BPD, corticosteroids may have to be given within the first few days after birth.
There has been concern that the benefits of corticosteroids might not outweigh the adverse effects, either short or long term [4] . Dexamethasone is the corticosteroid that has been most widely used systemically and evaluated in randomised controlled trials (RCTs). The only other systemic corticosteroid reported in RCTs is hydrocortisone; RCTs of hydrocortisone are reviewed elsewhere [5, 6] . The time of starting dexamethasone has varied broadly with the intent of the investigators either to treat evolving or established BPD, where treatment has started after the first week of life, or to prevent BPD where treatment is started during the first week of life. The difference in intent has been the basis for dividing the systematic reviews of RCTs of postnatal corticosteroids into those where treatment started in the first week [5] and those where treatment started after the first week [7] . Postnatal dexamethasone treatment has been shown to have some beneficial acute effects on lung function in babies with evolving or established BPD, especially those who are ventilator-dependent; those studies are reviewed elsewhere [7, 8] . The aim of this study was to examine the relative benefits and adverse effects of postnatal dexamethasone treatment started within the first 7 days of life to preterm infants at risk of developing BPD, but before it has become established. This report is a synthesis of the more clinically important outcomes of early postnatal dexamethasone which are detailed in the recently updated Cochrane Review [5] .
Methods
We included all randomised controlled trials of dexamethasone therapy in preterm infants at risk of developing BPD who were enrolled within the first 7 days of life (early postnatal dexamethasone), and where the comparison treatment was placebo. Studies included preterm infants who were ventilator-dependent at entry.
The types of outcome measures included mortality, BPD defined usually as oxygen dependency at either at 28 days or 36 weeks, death or BPD, late rescue with corticosteroids, survivors discharged home on oxygen, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal (GI) bleeding, GI perforation, severe retinopathy of prematurity (ROP), and long-term outcomes (including blindness, deafness, cerebral palsy and major neurosensory disability).
Randomised controlled trials of postnatal dexamethasone therapy were sought from the Cochrane Controlled Trials Register (CENTRAL), MEDLINE, hand-searching paediatric and perinatal journals, examining previous review articles and information received from practising neonatologists. MEDLINE was searched from 1966 through March 2009 using the terms adrenal cortex hormones or dexamethasone or steroids or corticosteroids, limits randomised controlled trials, human, all infant: birth -23 months. Authors of all studies were contacted, where possible, to confirm details of reported follow-up studies, or to obtain any information about long-term follow-up where none had been reported.
For each trial, information was sought regarding the method of randomisation, blinding, stratification, reporting of the outcome of all the infants enrolled. Information on the trial participants included the need for mechanical ventilation and the age when treatment was started. Meta-analysis of the included trials was performed using RevMan 5. For some statistically and clinically significant outcomes the number needed to treat for additional beneficial (NNTB) or harmful (NNTH) outcomes and 95% confidence intervals (CIs) were calculated from the typical relative risks according to methods of the Cochrane Handbook for Systematic Reviews of Interventions [9] , assuming the control group event rate as the baseline rate. Significant heterogeneity was present if the I 2 statistic was 1 50%, suggesting caution when interpreting the results of meta-analysis.
Results
Twenty trials, enrolling a total of 2,860 infants, qualified for inclusion in this review. Most of the trials enrolled low-birth-weight babies with RDS who were receiving mechanical ventilation; other characteristics are listed in table 1 . There was considerable variation with treatment regimens ranging from short courses of only 1 dose, to courses of up to 4 weeks; the median duration was 7 days. The median dose of dexamethasone in the protocols was 2.4 mg/kg, with a range from 0.2 to 14 mg/kg.
Details of individual trial methods are listed in table 2 . All were randomised trials, although the method of randomisation was not always clearly stated. In most treatment allocation was concealed from the study investigators. Blinding of intervention was concealed from the investigators by use of placebos, and most short-term outcomes were determined blinded to knowledge of treatment group allocation. Most had complete reporting of in-hospital outcomes for infants randomised. For the seven studies with long-term outcomes after discharge, the follow-up rates were good (80% and over) for all but one study. However, most children were assessed only before school-age.
Results of Meta-Analysis
The results of the meta-analysis of these 20 studies of early dexamethasone treatment, including the NNTB and NNTH where results were statistically significant, are shown in table 3 and figures 1 and 2 .
Mortality and Acute Lung Morbidity. There was little evidence that dexamethasone reduced mortality. However, it substantially reduced the rate of BPD at 28 days' postnatal age and at 36 weeks' postmenstrual age (PMA), the incidence of death or BPD at both 28 days' postnatal age and 36 weeks' PMA, the rate of failure to extubate by 7 days, and the proportion of infants receiving later corticosteroids. It did not reduce the rate of discharge home on oxygen, but this outcome was only reported for 3 studies (406 infants).
Complications during the Primary Hospitalisation.
Dexamethasone had other significant short-term benefits -it reduced the rate of PDA and of severe ROP. On the other hand, it had several significant short-term adverse effects, including higher rates of hyperglycaemia, hypertension, GI perforation, and GI bleeding, but there was little evidence of an effect on the incidence of NEC ( table 3 ) . There were also no substantial effects on rates of infection, pulmonary air leak, severe IVH or PVL.
Follow-Up Data. Of the 20 studies, only 7 (921 infants randomised) had follow-up data; most assessed children only in early childhood, with only one assessing them at school age [10] . The rates of cerebral palsy and combined mortality or cerebral palsy were significantly increased by dexamethasone. The reduction in severe ROP did not translate into a reduction in blindness, but blindness occurred infrequently. Rates of deafness, major neurosensory disability and the combined outcome of death or major neurosensory disability were not substantially affected. Pooled rates of selected outcomes for both treated and control groups, and the relative risks and 95% CIs for benefit are shown in figure 1 and for harm are shown in figure 2 .
Discussion
Very preterm infants with respiratory distress in the first week of life were helped in the short term by systemic dexamethasone treatment in the first days after birth, at least from a respiratory viewpoint, with reductions in failure to extubate, PDA, BPD, and the need for a later course of corticosteroids, as well as the combined outcome of death or BPD. However, these benefits came at the short-term cost of higher blood pressure and blood glucose, and also an excess of GI haemorrhage and perforation. Moreover, there were no short-or long-term benefits on mortality. Perhaps more importantly, the rates of cerebral palsy and the combined outcome of death or cerebral palsy were significantly higher in those treated with dexamethasone. On balance, the short-term benefits of early dexamethasone are outweighed by the increase in short-and long-term risks.
Of other possible corticosteroids, only hydrocortisone has been subjected to randomised controlled trials in humans. It has been used starting only in the first week of life, and not in infants with established BPD [5, 6] . Hy- drocortisone in these reported trials has had no clinically important benefits, possibly because the doses used have been quite low. On the other hand, hydrocortisone also causes GI perforation, like early dexamethasone, and cannot be recommended as treatment to prevent BPD. On balance there is no current evidence on which to base clinical use of any systemic corticosteroids in the first week of life to prevent BPD. Most of the studies reporting cerebral palsy as an outcome did so early in childhood, when the diagnosis of cerebral palsy is not certain in all cases [11] . In one study where the rate of cerebral palsy was significantly higher at 2 years of age [12] , the numbers of children with cerebral palsy declined between 2 and 8-9 years of age, and the difference became statistically non-significant [10] .
Part of the explanation for this may be because of the different ages of assessment, but another explanation may be the lower follow-up rate of 81% at 2 years compared with 92% at 8-9 years. No study has been designed primarily to test the effect of postnatal dexamethasone on adverse long-term neurosensory outcome, and all were underpowered to detect clinically important differences in long-term neurosensory outcome. Clearly more information on long-term outcome of infants is needed.
Virtually all of the trials are known to be confounded by open-label corticosteroid treatment, which makes it harder to determine the true effects, both beneficial and harmful, of dexamethasone alone. A subgroup analysis limited to those where it was certain there was no open- Future studies in preterm infants comparing different types, doses and durations of corticosteroids, and examining the effects of inhaled corticosteroids [13] are required to assess the overall risks and benefits of corticosteroids. Such studies should be sufficiently powered to detect important adverse long-term neurosensory sequelae, as the primary outcomes, and they should probably target infants at high risk of BPD [14] . Other ventilatory [15] and non-ventilatory [16, 17] strategies to prevent BPD should also be pursued.
In summary, the benefits of early postnatal dexamethasone in preterm infants at risk of developing BPD do not outweigh the real or potential adverse effects. There is a compelling need for the long-term follow-up and reporting of late outcomes, especially neurological outcomes, among survivors who participated in all randomised trials of early postnatal dexamethasone. Future studies are needed to identify accurately and early those infants most at risk of developing BPD, who might then be the subjects for any future randomised trials of postnatal corticosteroids, including dexamethasone.
